Representatives from both parties signed a memorandum of understanding (MoU) in Hanoi on 20/3. This event marks the next phase in their long-term commitment to "strengthening cancer patient care capacity in Vietnam," aiming to improve diagnostic and treatment capabilities, standardize clinical practices, and develop K Hospital's professional staff.

Upendra Patkie, general manager of Johnson & Johnson Innovative Medicine Vietnam, and K Hospital leaders shake hands after the MoU signing ceremony. Photo: Johnson & Johnson

Cancer has been one of the major health challenges for many years. According to Globocan data, in 2022 alone, Vietnam recorded about 180,480 new cases and 120,184 deaths due to cancer. These figures highlight the urgent need to improve early diagnosis, strengthen multidisciplinary treatment models, and ensure patients have timely access to healthcare services.

Among priority areas, three types of cancer – lung, prostate, and malignant hematologic diseases – pose significant clinical challenges. Specifically for lung cancer, some cases with mutations are not fully diagnosed due to limited patient awareness and testing procedures. Additionally, access to appropriate therapies is still under research and development.

A K Hospital representative noted that prostate cancer incidence is rising, yet access to advanced diagnostic methods and new-generation hormonal treatments remains limited. For hematologic diseases, enhancing diagnostic capabilities and standardizing treatment protocols are key factors for early intervention and improving long-term outcomes for patients with multiple myeloma and leukemia.

"Addressing these challenges requires strategic collaboration among stakeholders to promote early diagnosis, improve clinical decision-making quality, and expand opportunities for scientific exchange and research participation," K Hospital emphasized.

According to the MoU, both parties will focus on promoting professional training, scientific collaboration, and practical knowledge exchange in cancer treatment. Johnson & Johnson Vietnam will coordinate and support the implementation of scientific conferences, specialized workshops on research, scientific publications, continuing medical education (CME) programs, and a series of workshops on lung, prostate, and hematologic cancers.

Training activities for healthcare professionals will be expanded in the northern and north-central regions. This series of programs aims to enhance clinical knowledge and promote multidisciplinary treatment models, thereby supporting early, appropriate treatment decisions.

Upendra Patkie, general manager of Johnson & Johnson Innovative Medicine Vietnam, stated that K Hospital plays a crucial role in transferring oncology knowledge, disseminating treatment protocols, and promoting the application of clinical practices nationwide.

"Johnson & Johnson is pleased to partner with a key medical facility in the national cancer treatment system – where global scientific evidence is transformed into treatment protocols suitable for local realities. This MoU will help support earlier disease detection, strengthen science-based multidisciplinary treatment decisions, and thus enable more effective application of advancements in cancer care," Upendra Patkie added.

Leaders from both entities anticipate the strategic partnership will contribute significantly to cancer patient care in Vietnam. Photo: Johnson & Johnson

Since its inception, the Johnson & Johnson team has believed that "health is the foundation of all good things in life." With expertise in Innovative Medicine and MedTech, the corporation aims to build a world where complex diseases are prevented and definitively treated, researching a range of minimally invasive therapies and personalized healthcare solutions.

Dong Ve